Evidence map›Paper›PMID 28072848›Full record

ArticlePloS one2017

Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis.

Camille Rolland-Debord, Stephanie Fry, Jonathan Giovannelli, Carole Langlois, Nicolas Bricout, Bernard Aguilaniu, Agnes Bellocq, Olivier Le Rouzic, Stephane Dominique, Alain Delobbe and 4 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  3. Review
  4. Article
  5. How I manage pulmonary Langerhans cell histiocytosis.European respiratory review : an official journal of the European Respiratory Society · 2017
    Review
  6. New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis.European respiratory review : an official journal of the European Respiratory Society · 2017
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Camille Rolland-DebordService de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France.ORCID http://orcid.org/0000-0001-6455-6823
Stephanie FryService de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France.
Jonathan GiovannelliPôle de Santé Publique, Pharmacie et Pharmacologie, CHU Lille, Univ. Lille, Lille, France.
Carole LangloisService de Biostatistiques, CHU Lille, Univ. Lille, Lille, France.
Nicolas BricoutService de Radiologie, CHU Lille, Univ. Lille, Lille, France.
Bernard AguilaniuUniversité Joseph-Fourrier, Faculté de médecine, La Tronche, France.
Agnes BellocqUMRS 1158 Neurophysiologie respiratoire expérimentale et clinique, Sorbonne Universités, UPMC Univ Paris 06, INSERM, Paris, France.
Olivier Le RouzicService de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France.
Stephane DominiqueClinique Pneumologique, Hôpital Charles Nicolle, Université de Rouen, Centre Hospitalier Universitaire de Rouen, Rouen, France.
Alain DelobbeService de Pneumologie, Centre Hospitalier Régional de la citadelle, Liège, Belgique.
Geraldine FrançoisService de Pneumologie et Réanimation, Centre Hospitalier Universitaire d'Amiens, Université de Picardie Jules Verne, Amiens, France.
Abdellatif TaziService de Pneumologie, Centre de Référence de l'Histiocytose Langerhansienne, APHP - Hôpital Saint-Louis, Université Paris-Diderot, Sorbonne Paris Cité; INSERM UMR 1153 CRESS, Equipe de Recherche en Biostatistiques et Epidémiologie Clinique, Paris, France.
Benoit WallaertService de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France.
Cecile ChenivesseService de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReduced exercise capacity severely impacts quality of life in pulmonary Langerhans cell histiocytosis. Ascertaining mechanisms that impair exercise capacity is necessary to identify targets for symptomatic treatments.

methodsDyspnea, pulmonary function tests and cardiopulmonary exercise test were analysed in 62 study participants. Data were compared between subjects with impaired and normal aerobic capacity (V'O2 peak less than 84% versus 84% predicted or more). Data were reduced using a principal component analysis. Multivariate analysis included V'O2 peak as the dependent variable and principal components as covariates.

resultsV'O2 peak was reduced in 44 subjects (71%). Subjects with impaired aerobic capacity presented: (i) decreased FEV1, FVC, FEV1/FVC, DLCO and DLCO/VA and increased AaDO2, (ii) increased ventilatory equivalents at ventilatory threshold, VD/VT peak, AaDO2 peak and PaCO2 peak and decreased ventilatory reserve and PaO2 peak. There was no difference between groups in dyspnea scores. Principal component analysis extracted 4 principal components interpreted as follows: PC1: gas exchange; PC2: "pseudorestriction"; PC3: exercise-induced hyperpnea; PC4: air trapping. Multivariate analysis explained 65% of V'O2 peak. The 4 principal components were independently associated with V'O2 peak (βcoefficients: PC1: 9.3 [4.6; 14], PC2: 7.5 [3; 11.9], PC3: -5.3 [-9.6;-1.], PC4: -9.8 [-14,9;-4.7]).

conclusionImpaired exercise capacity is frequent in pulmonary Langerhans cell histiocytosis. It is mainly caused by pulmonary changes but is not associated with increased dyspnea intensity. Therefore, treating the lung represents a relevant approach for improving exercise capacity, even in patients experiencing mild dyspnea.

Indexed as

Exercise ToleranceAdultAnaerobic ThresholdDyspneaFemaleHistiocytosis, Langerhans-CellHumansMaleMiddle AgedRespiratory Function Tests

Identifiers

PMID28072848
PMCPMC5225005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.